Opinions Robert McWhirter
Bellus HealthBLU.TORISKYMar 18, 2019
The outlook is still quite good. People who use their competing chronic cough treatment lose their sense of taste. They are applying now for their drug's use for other conditions.
Robert McWhirterUnknown
N/A
Stock price when the opinion was issued
$19.32
As of Jun 29, 2023. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
RISKY
A pharma company working on a new drug for chronic cough. Early testing has produced good effectiveness and no nasty side effects. Tests should be completed within the year. He believes 60 to 300 patients are being tested. They have great potential. A speculative buy. It may become a takeover target.
biotechnologypharmaceutical
